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Letters to the Editor 
Dear Sir 
We read with the interest the recent article by 
Whiteford et al. (1) in which they found no 
relationship between dexamethasone nonsuppres- 
sion and negative symptoms in schizophrenic pa- 
tients. We feel that certain methodologic issues 
in this study specifically and the literature on the 
dexamethasone suppression test (DST) in schizo- 
phrenia in general merit closer scrutiny. In this 
study, all patients were receiving some neurolep- 
tic drug, which possess varying amounts of anti- 
cholinergic activity (2), and additionally half the 
patients (19 of 40) were also receiving anticholi- 
nergic medication. Cholinergic mechanisms play 
an important role in the regulation of the hypo- 
thalamic-pituitary-adrenal axis and increased 
cholinergic activity is associated with CRF re- 
lease and dexamethasone nonsuppression (3). 
Consequently, anticholinergic agents would in- 
terfere with results of the DST. 
Furthermore, patients in this study were in 
subacute/chronic phase of the illness and the 
overall rate of DST nonsuppression was found to 
be 22%. This is in contrast to rates of 71% (4) 
and 48% (5) found in unmedicated schizophren- 
ics in the acute phase of illness. Medication sta- 
tus and phase of illness are thus important varia- 
bles that influence the rates of dexamethasone 
nonsuppression in schizophrenic patients and 
possibly affect the association of this finding 
with negative symptoms. 
We performed a valid 1 mg DST in 20 schizo- 
phrenic inpatients (meeting RDC and DSM-I11 
criteria) at medication-free baseline and after 
about 4 weeks of treatment with neuroleptics (6). 
Patients were rated for positive and negative 
symptoms on the BPRS subscales and SANS 
respectively, and for depressive symptoms on the 
Hamilton Depression Rating Scale at both time- 
points. Seven of the 20 patients (35%) were 
nonsuppressors at baseline, but all of them had 
become suppressive following 4 weeks of neuro- 
leptic treatment. DST nonsuppression was not 
related to depressive symptoms. DST nonsup- 
pression was associated with: a) presence of base- 
line negative symptoms that remitted during hos- 
pitalization; b) acuteness of current psychotic 
episode; and c) good response to treatment. 
Thus, DST nonsuppression was associated 
with negative symptoms only in the acute phase 
of the illness and predicted a better outcome. We 
have proposed that muscarinic hyperactivity may 
be the pathogenetic basis of negative schizo- 
phrenic symptoms (7) and that cholinergic activ- 
ity increases in a homeostatic attempt to restore 
dopaminergic/cholinergic balance in the limbic 
system, this balance having being disrupted by 
the increased dopaminergic activity that attends a 
psychotic exacerbation in the acute phase of the 
illness. Thus, DST nonsuppression in schizophre- 
nia may reflect muscarinic hyperactivity, which is 
associated with negative symptoms in the acute 
phase of the illness and better clinical outcome 
(as the increase in cholinergic activity reflects a 
homeostatic attempt to restore doparninergid 
cholinergic balance). Although this hypothesis is 
speculative, it is consistent with various observa- 
tions and merits further investigation. 
Medication status and phase of assessment 
may account for the marked discrepancies in the 
literature with regard to the rates of dexametha- 
sone nonsuppression in schizophrenia (with rates 
varying from 0-71 qo), variable association of 
this finding with negative symptoms, and the 
prognostic significance of this finding. 
Rajiv Tandon 
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Dear Sir 
Ref: Hwu H-G, Yeh E-K, Chang L-Y. Preva- 
lence of psychiatric disorders in Taiwan defined 
by the Chinese Diagnostic Interview Schedule. 
Acta Psychiatr Scand 1989:79:136-147. 
In this article, the authors stated that (page 146, 
left column) “ ... a finding replicated by another 
independent study in Taiwan (24) using a dvfer- 
ent study method.” I think the word replicated 
has been used wrongly since: 1) The methods, as 
they have clearly pointed out, are quite different 
between their work and my own study; 2) Both 
of these studies were conducted during 1982- 
1985; 3) My work was published slightly earlier 
than theirs ( 1 ,  2). 
Tai Ann Cheng 
suppression test. Abstracts of the annual meeting of the 
Society of  Biological Psychiatry, 1988, Montreal. 
7. Tandon R, Greden JF. Cholinergic hyperactivity and negative 
schizophrenic symptoms: a model of cholinergic/dopaminer- 
gic interactions in schizophrenia. Unpublished manuscript. 
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